Adenoviral vector-mediated gene transfer to primitive human hematopoietic progenitor cells: assessment of transduction and toxicity in long-term culture
Kl. Mackenzie et al., Adenoviral vector-mediated gene transfer to primitive human hematopoietic progenitor cells: assessment of transduction and toxicity in long-term culture, BLOOD, 96(1), 2000, pp. 100-108
Adenoviral gene transfer to primitive hematopoietic progenitor cells (HPCs)
would be useful in gene therapy applications where transient, high-level t
ransgene expression is required. In the present Investigations, we have use
d an adenoviral vector expressing the green fluorescent protein (AdGFP) to
quantify transduction of primitive HPCs and assess adenoviral-associated to
xicity in long-term culture. Here we show that a cytokine cocktail protects
mass populations of CD34(+) cells and primary colony forming unit-cultures
(CFU-Cs) from toxicity, enabling transduction of up to 79% of CD34(+) cell
s. Transduction of CFU-Cs primitive (HPCs) and more primitive HPCs was quan
tified following fluorescence activated cell sorting for green flourescence
protein expression, Our results demonstrate transduction of 45% of primary
CFU-Cs, 33% of week-5 cobblestone area forming cells (CAFCs), and 18% of w
eek-5 CFU-Cs. However, AdGFP infection inhibited proliferation of more prim
itive cells. Although there was no apparent quantitative change in week-5 C
AFCs, the clonogenic capacity of week-5 AdGFP-infected cells was reduced by
40% (P < .01) when compared with mock-infected cells. Adenoviral toxicity
specifically affected the transduced subset of primitive HPCs. Transduction
of primitive cells is therefore probably underestimated by week-5 CFU Cs a
nd more accurately indicated by week-5 CAFCs. These studies provide the fir
st functional and quantitative evidence of adenoviral transduction of primi
tive HPCs. However, further investigations will be necessary to overcome ad
enoviral toxicity toward primitive HPCs before adenoviral vectors can be co
nsidered a safe option for gene therapy. (Blood. 2000;96:100-108) (C) 2000
by The American Society of Hematology.